{
    "clinical_study": {
        "@rank": "85717", 
        "acronym": "IVENT", 
        "arm_group": {
            "arm_group_label": "Iloprost", 
            "description": "The patients with pulmonary hypertension with inhaled treatment with Ventavis according to routine practice meeting the criteria of inclusion."
        }, 
        "brief_summary": {
            "textblock": "Local, prospective, multicenter, non-comparative, non-interventional, observational study.\n      It is planed to assess compliance of patients with PH (pulmonary hypertension) with the\n      physician's recommendation in real practice."
        }, 
        "brief_title": "Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension, Pulmonary", 
        "condition_browse": {
            "mesh_term": [
                "Hypertension", 
                "Hypertension, Pulmonary"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female patients \u2265 18 years old\n\n          -  Diagnosis of PH\n\n          -  Planned or current treatment with Ventavis (not more than 6 month)\n\n        Exclusion Criteria:\n\n          -  Contraindications for the use of Ventavis in accordance with the local product\n             information"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Male and female patients \u2265 18 years old with PH, treated with Ventavis and for which the\n        inclusion and exclusion criteria are fulfilled, are eligible for enrolment into the study."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01971450", 
            "org_study_id": "16777", 
            "secondary_id": "VE1311RU"
        }, 
        "intervention": {
            "arm_group_label": "Iloprost", 
            "intervention_name": "Iloprost (Ventavis, BAYQ6256)", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Iloprost"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Non-interventional", 
            "Ventavis", 
            "Iloprost", 
            "Pulmonary hypertension", 
            "Compliance", 
            "Russian Federation"
        ], 
        "lastchanged_date": "May 16, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Many locations", 
                    "country": "Russian Federation"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Russian Federation"
        }, 
        "number_of_groups": "1", 
        "official_title": "Prospective Multicentre Non-interventional Study on Compliance of Inhaled Treatment With Ventavis in Patient With Pulmonary Hypertension", 
        "overall_contact": {
            "email": "clinical-trials-contact@bayerhealthcare.com", 
            "last_name": "Bayer Clinical Trials Contact"
        }, 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Russia: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Number of fully inhaled doses per day versus the recommended number as a measure of compliance", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "measure": "Number of fully inhaled doses in total versus the recommended number as a measure of compliance", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01971450"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "6 minute walking distance test (MWDT) value", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "measure": "Score on dyspnea Borg CR (category ratio) 10 scale", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "measure": "Patients' quality of life, assessed by validated questionnaire", 
                "safety_issue": "No", 
                "time_frame": "Up to 12 months"
            }, 
            {
                "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 months"
            }
        ], 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}